Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease

被引：14

作者：

Corbalán, R

Miñana, MD

Del Olmo, JA

Serra, MA

Rodrigo, JM

Felipo, V

机构：

[1] Fdn Valenciana Invest Biomed, Inst Invest Citol, Neurobiol Lab, Valencia 46010, Spain

[2] Organismo Publ Valenciano Invest, Inst Biol Celular, Valencia, Spain

[3] Univ Valencia, Hosp Clin, Unidad Hepatol, Valencia 46010, Spain

来源：

JOURNAL OF MOLECULAR MEDICINE-JMM | 2002年 / 80卷 / 02期

关键词：

cGMP; hepatic encephalopathy; hyperammonemia; nitric oxide;

D O I：

10.1007/s00109-001-0286-2

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Studies of animal models suggest that the activation of soluble guanylate cyclase by nitric oxide is altered in liver disease. We studied 77 patients with liver disease and 17 controls, to investigate whether the activation of soluble guanylate cyclase is altered in lymphocytes from patients with liver disease. The basal content of guanosine 3',5'-cyclic monophosphate (cGMP) in lymphocytes was decreased both in patients with liver cirrhosis (by 52%) and in patients with chronic hepatitis (by 62%). Activation of soluble guanylate cyclase by nitric oxide was higher in lymphocytes from patients with cirrhosis (3100+/-1000% of basal) or with hepatitis (5200+/-2500% of basal) than in lymphocytes from controls (1200+/-500% of basal). cGMP in plasma was increased in patients with liver disease. Successful (but not unsuccessful) treatment with interferon of patients with hepatitis due to virus C reversed all the above alterations. Altered modulation of soluble guanylate cyclase by nitric oxide in liver disease may play a role in the hemodynamic alterations found in these patients.

引用

页码：117 / 123

页数：7

共 25 条

[1] Binding characterization of a putative cGMP transporter in the cell membrane of human erythrocytes [J].